Cancer Vaccines Industry Research Report 2024: Market Poised for Exponential Growth with a Projected Value of $6.7 Billion by 2032 [Yahoo! Finance]
Anixa Biosciences, Inc. (ANIX)
Last anixa biosciences, inc. earnings: 3/9 05:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering. A comprehensive study of the global cancer vaccines market has revealed a substantial growth trajectory, with projections indicating a market value increase to US$ 16.7 Billion by the year 2032. This growth, demonstrating a CAGR of 10.5% during the forecast period from 2023 to 2032, is primarily driven by rising incidence of cancer, developments in immunotherapy, and a surge in healthcare initiatives and funding. The landscape consists of two main types of vaccines—preventive and therapeutic. The market is currently led by preventive vaccines, which have been integral in combatting cancer occurrence related to infectious agents, manifested in the successful adoption of HPV and HBV vaccines. Therapeutic vaccines, meanwhile, are gaining traction for their capacity to treat existing cancers, particularly through personalized medicine strategies. Key Market Drivers Several factors are propellin
Show less
Read more
Impact Snapshot
Event Time:
ANIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIX alerts
High impacting Anixa Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ANIX
News
- Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingPR Newswire
- Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingPR Newswire
- Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024PR Newswire
- Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingPR Newswire
ANIX
Earnings
- 9/6/24 - Beat
ANIX
Analyst Actions
- 9/17/24 - HC Wainwright
ANIX
Sec Filings
- 11/8/24 - Form 8-K
- 10/23/24 - Form 4
- 9/6/24 - Form 10-Q
- ANIX's page on the SEC website